Argenica Therapeutics

Announcements

New investors

Home

Updates

Lora

Listen on Spotify

Listen on Apple Podcasts

Listen on Equity Mates Investing (Spotify | Apple)

Uncovered is our series where we take a closer look at some of the Aussie companies that get less analyst coverage and media attention. And today’s episode is a cracker.

When it comes to strokes, there is a saying: time is brain.

During a stroke, blood vessels are blocked and blood carrying essential oxygen cannot make it to brain cells. This lack of oxygen kills 1.9 million brain cells every minute. Sadly, globally, only 35% of patients suffering from an acute stroke arrive at hospital in the critical 4.5 hour window for treatment. As such, stroke researchers around the world are focused on shortening the time to treatment.

Argenica Therapeutics are approaching this problem slightly differently. Rather than trying to get the patient to hospital within the 4.5 hour window, they’ve asked: how can we widen that 4.5 hour window?

To better understand their work, today we speak to Argenica Therapeutics CEO and Managing Director, Dr Liz Dallimore.

Want more? Read our write up on Argenica Therapeutics

Want to ask a question or join us on the podcast, hit us up via our website.